Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug developed at UC Davis may prevent breast cancer, treat post-menopausal vaginal atrophy

03.11.2005


20-year collaboration between UC Davis and Finnish researchers led to new drug



A tamoxifen-like drug developed by UC Davis and Finnish researchers, now in clinical testing as a treatment for vaginal atrophy, may also help to prevent breast cancer, two preliminary studies suggest.

The studies, based on research in a mouse model of human breast cancer, will be published in the November issue of the Journal of Steroid Biochemistry and Molecular Biology and the December issue of Breast Cancer Research.


"These reports indicate that prevention of breast cancer may be another benefit of the use of ospemifine," said Michael W. DeGregorio, a professor of medicine at UC Davis. "The findings are very encouraging."

DeGregorio is senior author of the November article and a contributing author of the December paper. He has spent the last 20 years developing ospemifene in collaboration with Risto Lammintausta, managing director of Hormos Medical Corp. in Turku, Finland.

Ospemifene is now being developed by QuatRx Pharmaceuticals, an Ann Arbor, Mich.-based biopharmaceutical company that recently merged with Hormos Medical Corp. The drug is expected to enter Phase 3 clinical testing in the United States early next year for the treatment of vaginal atrophy, a common condition among postmenopausal women.

Ospemifene is one of a class of drugs called selective estrogen receptor modulators. The well-known agent tamoxifen, used to prevent breast cancer in women at high risk for the disease, and raloxifen, currently used to prevent bone fractures in women with osteoporosis, belong to the same class.

In the Journal of Steroid Biochemistry and Molecular Biology, DeGregorio and his colleagues at UC Davis compared the ability of ospemifene, tamoxifen and raloxifen to inhibit breast cancer in mice exposed to a carcinogen. Ospemifene and tamoxifen both inhibited breast cancer development: Mice in the ospemifene group were 95 percent less likely than mice in the control group to develop breast cancer. Raloxifen had no such effect. The study is available online in advance of its publication in print at www.sciencedirect.com.

The second study, led by Jeffrey P. Gregg, an associate professor of pathology and laboratory medicine at UC Davis, reports that in a mouse model, both tamoxifen and ospemifene inhibited the growth and progression of pre-malignant breast lesions that closely resemble human ductal carcinomas in situ. Both these agents decreased the growth of the lesions by reducing the proliferation rate of the precancerous cells.

The article is available online in advance of its print publication date at www.breast-cancer-research.com.

While similar, tamoxifen, raloxifen and ospemifine have variations in chemical structure that give them unique therapeutic profiles. For example, raloxifen can prevent bone fractures, but it can also cause hot flashes, insomnia and blood clots. Tamoxifen can decrease a high-risk woman’s odds of developing breast cancer by half, but the drug also increases the risk of endometrial cancer and can cause the same side effects as raloxifen.

In clinical tests so far, ospemifene appears to have a unique estrogen-like effect on the vagina, yet a neutral effect on the endometrium, or lining of the uterus, and no aggravation or initiation of hot flashes. Results of the Phase 1 and Phase 2 tests, conducted in postmenopausal women in Finland, appear in the journal Menopause in September 2003 and March 2005.

"Dr. Lammintausta and I worked for many years to find a drug that would have beneficial effects in healthy, postmenopausal women but be absolutely safe," said DeGregorio. "We’re gratified that this seems to be the case."

Decreased estrogen levels can lead to a thinner, less elastic and more fragile vaginal lining. Known as vaginal atrophy, the problem affects 10 to 40 percent of post-menopausal women. Symptoms may include dryness, itching, burning, irritation, a feeling of pressure, and pain or light bleeding with sex. Estrogen creams, rings, patches or oral supplements are often prescribed to treat vaginal atrophy.

Claudia Morain | EurekAlert!
Further information:
http://www.ucdmc.ucdavis.edu

More articles from Life Sciences:

nachricht Link Discovered between Immune System, Brain Structure and Memory
26.04.2017 | Universität Basel

nachricht Researchers develop eco-friendly, 4-in-1 catalyst
25.04.2017 | Brown University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Scientist invents way to trigger artificial photosynthesis to clean air

26.04.2017 | Materials Sciences

Ammonium nitrogen input increases the synthesis of anticarcinogenic compounds in broccoli

26.04.2017 | Agricultural and Forestry Science

SwRI-led team discovers lull in Mars' giant impact history

26.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>